Global Gene Therapy Market to Reach US$ 16.8 Billion by 2032, Propelled by Rising Prevalence of Genetic and Acquired Diseases

February 15, 2022 | Healthcare

The latest report by IMARC Group, titled "Gene Therapy Market Report by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide Gene, Deficiency, Growth Factors, Receptors, and Others), Vector Type (Viral Vector, Non-Viral Techniques), Delivery Method (In-Vivo Gene Therapy, Ex-Vivo Gene Therapy), Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Others), and Region 2024-2032," finds that the global gene therapy market size reached US$ 5.1 Billion in 2023. Gene therapy refers to an advanced medical technique that involves modifying the genes inside the cells of the patient's body to treat or prevent the progression of the disease. It works by replacing a defective gene with a new, normal and healthy gene in a cell to cure the disease or improve the body's ability to fight it. It is also used to treat numerous chronic and genetic disorders in human beings that have no other cures. Nowadays, manufacturers are offering a wide variety of gene therapy products, including plasmid deoxyribonucleic acid (DNA), human gene-editing technology, patient-derived cellular gene therapy, viral vectors, and bacterial vectors, which is currently escalating their demand across the globe.

Global Gene Therapy Market Trends:

The rising prevalence of genetic and acquired diseases, such as cancer, diabetes, cardiovascular diseases (CVDs), cystic fibrosis, and acquired immunodeficiency syndrome (AIDS), represents the primary factor driving the market growth. Besides this, the expanding geriatric population that is more susceptible to developing such chronic health conditions has catalyzed the product demand. Additionally, there has been a significant increase in government support and funding for gene therapy research. Along with this, the growing awareness regarding the benefits of gene therapy and easy accessibility to healthcare facilities have accelerated the product adoption rate. Furthermore, several key players are engaging in research and development (R&D) activities and making heavy investments toward product innovations to gain a competitive edge. Moreover, the introduction of new gene therapy that provides a safer and non-addictive alternative to opioids in treating various chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, has propelled the market growth. Other factors, including the increasing approvals of gene therapy products, favorable reimbursement policies, improving healthcare infrastructure, rising consumer healthcare expenditure, and technological advancements, are also providing a positive impact on the market growth. Looking forward, IMARC Group expects the market to reach US$ 16.8 Billion by 2032, growing at a CAGR of 13.9% during 2024-2032.

Market Summary:

  • Based on the gene type, the market has been segregated into antigen, cytokine, tumor suppressor, suicide gene, deficiency, growth factors, receptors, and others.
  • The market has been divided based on the vector type into viral vector (adenoviruses, lentiviruses, retroviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others) and non-viral techniques (naked and plasmid vectors, gene gun, electroporation, lipofection, and others).
  • Based on the delivery method, the market has been bifurcated into in-vivo and ex-vivo gene therapy.
  • On the basis of the application, the market has been classified into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and others.
  • Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.  
  • The competitive landscape of the market has also been analyzed, with some of the key players being Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis International AG, Orchard Therapeutics plc, UniQure N.V., and Voyager Therapeutics Inc.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Gene Type, Vector Type, Delivery Method, Application, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Gene Therapy Market to Reach US$ 16.8 Billion by 2032, Propelled by Rising Prevalence of Genetic and Acquired Diseases
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More